Share

RxSight Inc (RXST.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 18 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

Diversity of Models

Diversity of Frameworks

Warren Buffett AI

Gemini 3.8 Flash

The Value Seeker FrameworkAI Thinker

Price-adjusted rating

Strong Buy

5-Year Return Est.

+761.9%

RXST.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

RxSight represents an exceptional mispricing where Mr. Market offers a wonderful medical franchise at a fire-sale valuation. While recent elective surgery slowdowns caused revenue to stall near $128 million TTM, the core economic engine remains profoundly intact. The proprietary Light Delivery Device creates an expanding installed base that drives high-margin, recurring Light Adjustable Lens sales at a staggering 76.6% gross margin. Backed by a pristine balance sheet with nominal debt and ample liquidity, RxSight possesses the staying power to achieve operating profitability without diluting shareholders, unlocking immense long-term value.

A cash fortress of roughly $250 million in net liquidity ensures self-funded runway through projected operating breakeven.
Trading at 0.82 times book value, the enterprise value sits near zero, presenting an asymmetrical margin of safety.
Reaching $200 million in recurring revenue at 78% implies over $40 million in normalized owner earnings.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-16	13.00
Observed price	2021-09-20	12.51
Observed price	2021-10-06	13.63
Observed price	2021-10-14	13.65
Observed price	2021-10-22	11.73
Observed price	2021-11-15	12.08
Observed price	2021-11-19	13.52
Observed price	2021-12-09	12.25
Observed price	2021-12-17	10.26
Observed price	2022-01-06	9.28
Observed price	2022-01-10	11.50
Observed price	2022-01-22	11.13
Observed price	2022-01-30	10.18
Observed price	2022-02-07	11.36
Observed price	2022-02-27	13.62
Observed price	2022-03-07	13.27
Observed price	2022-03-19	11.80
Observed price	2022-03-27	12.37
Observed price	2022-04-08	13.24
Observed price	2022-04-20	13.27
Observed price	2022-05-06	11.35
Observed price	2022-05-14	12.42
Observed price	2022-06-03	16.00
Observed price	2022-06-07	16.40
Observed price	2022-06-19	13.13
Observed price	2022-07-01	15.18
Observed price	2022-07-17	13.62
Observed price	2022-08-10	15.85
Observed price	2022-08-14	13.88
Observed price	2022-08-18	14.44
Observed price	2022-08-30	12.37
Observed price	2022-09-11	14.11
Observed price	2022-09-27	11.22
Observed price	2022-10-05	11.74
Observed price	2022-10-09	10.28
Observed price	2022-11-02	11.79
Observed price	2022-11-14	13.88
Observed price	2022-11-26	11.99
Observed price	2022-12-04	13.95
Observed price	2022-12-20	11.17
Observed price	2023-01-05	12.85
Observed price	2023-01-25	12.90
Observed price	2023-01-29	13.96
Observed price	2023-02-02	13.99
Observed price	2023-02-10	12.82
Observed price	2023-03-02	13.36
Observed price	2023-03-06	15.69
Observed price	2023-03-22	15.87
Observed price	2023-04-11	17.24
Observed price	2023-04-19	17.40
Observed price	2023-05-01	18.80
Observed price	2023-05-09	19.25
Observed price	2023-05-21	25.9
Observed price	2023-06-18	25.8
Observed price	2023-06-22	26.8
Observed price	2023-06-26	25.5
Observed price	2023-07-16	32.7
Observed price	2023-07-28	33.3
Observed price	2023-08-09	27.6
Observed price	2023-08-17	29.6
Observed price	2023-08-29	28.7
Observed price	2023-09-10	29.8
Observed price	2023-09-22	27.2
Observed price	2023-09-30	27.5
Observed price	2023-10-12	24.4
Observed price	2023-10-28	21.2
Observed price	2023-11-13	25.9
Observed price	2023-11-17	27.5
Observed price	2023-12-07	34.2
Observed price	2023-12-11	35.0
Observed price	2023-12-27	40.9
Observed price	2024-01-04	35.6
Observed price	2024-01-24	46.4
Observed price	2024-02-05	46.7
Observed price	2024-02-17	55.2
Observed price	2024-03-04	56.1
Observed price	2024-03-12	50.7
Observed price	2024-03-16	47.0
Observed price	2024-04-05	55.2
Observed price	2024-04-09	55.1
Observed price	2024-04-25	51.9
Observed price	2024-05-11	59.1
Observed price	2024-05-15	64.3
Observed price	2024-05-27	61.0
Observed price	2024-06-16	56.7
Observed price	2024-06-28	60.2
Observed price	2024-07-10	51.1
Observed price	2024-07-14	48.3
Observed price	2024-08-03	41.4
Observed price	2024-08-07	46.2
Observed price	2024-08-27	56.6
Observed price	2024-08-31	55.6
Observed price	2024-09-20	53.0
Observed price	2024-10-02	47.6
Observed price	2024-10-14	50.3
Observed price	2024-10-22	50.3
Observed price	2024-10-30	51.2
Observed price	2024-11-15	45.0
Observed price	2024-11-27	46.4
Observed price	2024-12-05	42.3
Observed price	2024-12-21	34.0
Observed price	2025-01-06	35.4
Observed price	2025-01-14	30.1
Observed price	2025-01-22	31.9
Observed price	2025-02-03	33.7
Observed price	2025-02-19	30.7
Observed price	2025-03-07	25.1
Observed price	2025-03-19	24.9
Observed price	2025-03-27	26.7
Observed price	2025-04-04	16.26
Observed price	2025-04-12	14.19
Observed price	2025-05-02	15.85
Observed price	2025-05-14	13.24
Observed price	2025-05-26	15.93
Observed price	2025-06-11	14.91
Observed price	2025-06-15	14.13
Observed price	2025-06-27	12.67
Observed price	2025-07-21	7.35
Observed price	2025-07-25	7.97
Observed price	2025-08-10	6.83
Observed price	2025-08-22	9.28
Observed price	2025-08-26	8.50
Observed price	2025-09-11	9.42
Observed price	2025-09-23	9.46
Observed price	2025-10-09	8.11
Observed price	2025-10-13	7.57
Observed price	2025-11-02	8.72
Observed price	2025-11-06	8.61
Observed price	2025-11-26	11.52
Observed price	2025-11-30	11.57
Observed price	2025-12-16	12.76
Observed price	2025-12-24	11.46
Observed price	2026-01-09	8.84
Observed price	2026-01-21	9.95
Observed price	2026-02-06	8.39
Observed price	2026-02-22	8.78
Observed price	2026-03-02	7.61
Observed price	2026-03-06	7.69
Observed price	2026-03-22	6.41
Observed price	2026-03-30	6.09
Observed price	2026-04-19	7.50
Observed price	2026-05-01	7.40
Observed price	2026-05-13	5.55
Observed price	2026-05-21	6.35
Observed price	2026-06-02	4.94
Observed price	2026-06-10	4.60
Observed price	2026-06-26	5.36
Observed price	2026-07-12	5.02
Observed price	2026-07-20	5.61
Observed price	2026-07-28	6.05
Observed price	2026-08-13	7.01
Observed price	2026-08-29	7.14
Observed price	2026-09-10	5.96
Observed price	2026-09-14	6.11
Observed price	2026-09-21	5.14
Published advisor forecast	2026-09-18	5.20
Published advisor forecast	2026-12-18	5.62
Published advisor forecast	2027-03-18	6.29
Published advisor forecast	2027-06-18	7.23
Published advisor forecast	2027-09-18	7.96
Published advisor forecast	2027-12-18	9.39
Published advisor forecast	2028-03-18	10.70
Published advisor forecast	2028-06-18	12.42
Published advisor forecast	2028-09-18	13.78
Published advisor forecast	2028-12-18	15.85
Published advisor forecast	2029-03-18	17.75
Published advisor forecast	2029-06-18	19.35
Published advisor forecast	2029-09-18	22.1
Published advisor forecast	2029-12-18	24.3
Published advisor forecast	2030-03-18	27.2
Published advisor forecast	2030-06-18	29.3
Published advisor forecast	2030-09-18	32.6
Published advisor forecast	2030-12-18	34.9
Published advisor forecast	2031-03-18	38.3
Published advisor forecast	2031-06-18	40.6
Published advisor forecast	2031-09-18	44.3

2. Scenarios & Signals

Bull case

Accelerated surgeon adoption ignites a virtuous cycle as international regulatory approvals unlock European and Asian markets simultaneously. Consumable lens reorder rates surge past 25% annually, propelling toward 80% and driving rapid operating leverage. With free cash flow turning solidly positive ahead of schedule, institutional investors aggressively bid the stock back toward historical multiples. This explosive operational convergence drives multi-bagger equity repricing.

Bear case

Prolonged stagflation and persistent consumer real-income erosion permanently stifle patient willingness to fund premium out-of-pocket cataract upgrades. Simultaneously, aggressive bundling and heavy discounting by incumbent conglomerates stall new Light Delivery Device placements below replacement rates. Operating losses persist, steadily draining liquid reserves and eventually forcing dilutive equity financing in an unfavorable market. Consequently, the share price languishes below current indefinitely.

Current crowd narrative

The consensus treats RxSight as a broken medtech story whose growth engine stalled out in 2025. Wall Street fixates entirely on recent quarterly revenue contractions and negative free cash flow, pricing the stock at a distressed 0.82 times . Investors mistakenly assume that sluggish capital equipment placements signal platform obsolescence, completely ignoring the resilient high-margin consumable razor-and-blade model.

Alpha-gap assessment

The crowd vastly overestimates insolvency risk and undervalues RxSight's extraordinary economic moat. Mr. Market is treating a debt-free enterprise possessing $276 million in equity and 76.6% as if it were a distressed biotech facing liquidation. The blind spot lies in confusing cyclical hesitation in clinic capital purchases with permanent erosion of clinical utility. In reality, the swelling guarantees recurring lens demand, making today's $5.20 quote an astounding mispricing against underlying intrinsic worth.

Convergence catalyst

Quarterly operating cash-flow breakeven, likely materializing by late 2027 or early 2028 as lens consumable volumes expand, represents the definitive repricing catalyst. The first unmistakable sign will be consecutive quarters of positive , forcing institutional consensus to re-rate RxSight from a cash-burning speculative device to a profitable medical moat.

Macro-regime alignment

The prevailing regime of 3.75%-4.00% policy rates and sticky consumer inflation exerts a manageable near-term headwind on elective out-of-pocket medical procedures and clinic debt financing. However, RxSight's nearly debt-free balance sheet insulates it from higher borrowing costs, leaving the underlying thesis predominantly tethered to secular healthcare demand rather than macro-cyclical swings.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.7
Expected volatility regime: high_erratic
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Razor AND Blade Consumable Margin Expans	RxSight's expanding Light Delivery Device install base creates an enduring, captive annuity stream of Light Adjustable Lens procedures. Gross margins expanded remarkably from 11.6% in 2020 to 76.6% in 2025, proving tremendous structural pricing power. As procedure volume absorbs fixed manufacturing overhead, every incremental lens drops directly to gross profit, fueling a sustainable operating trajectory.	Not available	+65.0%
Operating Leverage AND Expense Rationali	Having established extensive direct commercial infrastructure across North America, management can moderate salesforce expansion and optimize commercial spend. R&D spending flattened at $38.5 million in 2025, setting up rapid operating leverage as top-line revenue surpasses cash break-even. The resulting elimination of cash burn transforms the business from an equity-depleting startup into a self-funding compounder.	Not available	+50.0%
Clinical Superiority Drives Surgeon LOCK	Post-operative refractive customization eliminates the biometry guesswork that plagues traditional multifocal lenses, granting ophthalmic surgeons unparalleled visual acuity outcomes. Once clinics commit capital and staff training to the Light Delivery Device workflow, switching barriers become extraordinarily prohibitive. This clinical moat guarantees sustained utilization rates across leading ambulatory surgery centers over the five-year horizon.	Not available	+45.0%
Secular Demographic Tailwinds IN Catarac	An aging global population and rising expectations for spectacle independence underpin resilient long-term demand for premium intraocular lenses. Despite cyclical pauses in elective healthcare spending, the non-discretionary clinical necessity of cataract surgery ensures volume recovery. RxSight is strategically positioned to capture high-margin market share from legacy monofocal and conventional toric alternatives as volumes normalize.	Not available	+40.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Elective Healthcare Consumer Spending SQ	High interest rates and sticky inflation strain household budgets, pressuring discretionary healthcare spending where patients must pay significant out-of-pocket premiums for adjustable lenses. When macroeconomic anxiety flares, patients often default to standard, insurance-reimbursed monofocal options. This consumer hesitation directly throttles procedure conversion rates, capping near-term revenue acceleration and delaying the timeline to operating profitability.	Not available	-25.0%
Capital Expenditure Freezes AT Ambulator	Persistent tightening in credit markets and elevated hospital financing costs constrain ambulatory surgery centers from purchasing expensive new capital equipment like the Light Delivery Device. When institutional borrowing costs rise, facility administrators defer upfront equipment placements. This headwind slows system placement velocity, extending the adoption cycle and dampening the high-margin recurring lens sales that follow placements.	Not available	-20.0%
Competitive Retaliation FROM Entrenched	Well-capitalized ophthalmology titans like Alcon and Johnson & Johnson fiercely defend their premium IOL franchises with bundled pricing, aggressive rebate programs, and massive clinical sales forces. While their conventional toric and multifocal lenses lack post-op adjustability, their entrenched distribution channels restrict RxSight's commercial penetration speed. This incumbent friction forces RxSight to maintain elevated marketing and surgeon-education expenditures.	Not available	-15.0%
Procedural Workflow AND Scheduling Frict	The multi-session post-operative light adjustment protocol requires additional clinic visits and optometrist coordination compared to standard one-and-done intraocular lens surgeries. This procedural complexity imposes capacity constraints on busy ophthalmic practices facing ongoing healthcare staffing shortages. Practices that cannot streamline patient scheduling experience lower utilization throughput, creating an operational drag on consumable lens reorder velocity.	Not available	-12.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Strategic Buyout BID BY Medtech Conglomerate	A cash-rich medical device conglomerate seeking to dominate premium ophthalmic surgery could launch an unsolicited buyout offer for RxSight's proprietary technology. RxSight's deflated market capitalization of $216 million presents an extraordinarily accretive tuck-in target for players like Alcon or Zeiss. Although management's independent commercial ambition keeps this catalyst below 50% probability, an acquisition offer would instantly deliver a massive control premium.	25.0%	+110.0%
International Regulatory Clearances AND Commercial	Gaining formal regulatory approvals and establishing commercial distribution across Europe, Japan, and key Asian markets would instantly multiply RxSight's addressable cataract volume. A coordinated international rollout triggered by CE Mark or PMDA greenlights would ignite explosive high-margin LAL adoption abroad. Given stringent local clinical trial barriers, material revenue contribution remains below 50% probability before 2028, but realization would expand international revenues dramatically.	35.0%	+75.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Severe POST Operative Photochemical Toxicity Recal	A cluster of unforeseen post-operative photochemical macular toxicity cases or severe lens material degradation could prompt an FDA investigation and black-box warning or product recall. Such an event would shatter ophthalmologist confidence, halt elective patient scheduling overnight, and trigger catastrophic legal liabilities. Although extensive clinical safety records make this catastrophe improbable, materialization would permanently impair enterprise earning power.	12.0%	-70.0%
Disruptive NON Invasive Adjustable LENS Emergence	The sudden clinical validation of a competing non-invasive adjustable lens or accommodating IOL technology by a rival could undermine RxSight's technological moat. If an alternative delivers true post-operative customization without requiring multi-visit UV light treatments, surgeon demand could rapidly abandon the LAL platform. While clinical trials and regulatory timelines make near-term obsolescence unlikely, it poses an existential threat to terminal value.	18.0%	-55.0%

Step-by-step forecast path

Warren Buffett forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_539ccef7-a685-5f65-8e02-5b2f22eaca75__sb7__20260920053028116336
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+8.0%	5.62	Tax-loss selling pressure abates, while late-year surgical procedures confirm stable consumable lens demand. Discerning value investors recognize the absurd discount to tangible book value, establishing a firm valuation floor for the shares.
2	March 18, 2027	+12.0%	6.29	Full-year 2026 financial results confirm moderating operational cash burn and resilient 76% gross margins. Executive commentary confirms that existing cash reserves provide an ample bridge to profitability, reassuring skeptical market participants.
3	June 18, 2027	+15.0%	7.23	Ambulatory surgery centers deploy updated capital budgets, reigniting Light Delivery Device placements. Concurrently, seasonal spring cataract surgery volumes lift recurring, high-margin consumable lens sales across North American commercial territories.
4	September 18, 2027	+10.0%	7.96	First-half financial results demonstrate that commercial sales expenditures have stabilized while procedure volumes expand. The resulting display of operating leverage ignites disciplined institutional accumulation, driving steady upward equity price discovery.
5	December 18, 2027	+18.0%	9.39	Third-quarter disclosures reveal quarterly cash burn narrowing below $4 million as high-margin lens sales surge. Valuation multiple expansion accelerates as Mr. Market rapidly eliminates catastrophic dilution risk from the share price.
6	March 18, 2028	+14.0%	10.70	Full-year 2027 earnings communicate an impending inflection toward positive operating cash flow. Sell-side analysts aggressively revise long-term earnings projections upward as the razor-and-blade commercial model proves its structural earning power.
7	June 18, 2028	+16.0%	12.42	RxSight achieves its inaugural quarter of positive operating cash flow, marking a historic fundamental inflection point. Skeptical short sellers are forced to liquidate positions, triggering an energetic upward repricing across public markets.
8	September 18, 2028	+11.0%	13.78	Consumable lens revenues surpass 70% of total company turnover, proving the self-sustaining nature of the business. Gross margins expanding toward 78% reinforce the widening clinical and operational moat against entrenched competitors.
9	December 18, 2028	+15.0%	15.85	European regulatory clearance milestones unlock pivotal commercial distribution agreements across leading private eye clinics. Accelerating unit volume and expanding international awareness drive robust mid-cycle valuation multiple expansion for the common stock.
10	March 18, 2029	+12.0%	17.75	Annual 2028 financial statements confirm positive annual EBITDA, cementing RxSight's transition into a self-funding enterprise. The fortress balance sheet remains completely unencumbered without having incurred any dilutive debt or equity financing.
11	June 18, 2029	+9.0%	19.35	Resilient domestic cataract volumes withstand broader macroeconomic fluctuations, highlighting the non-discretionary medical demand for vision restoration. Sustained high-margin procedure volume maintains impressive top-line stability and healthy quarterly free cash generation.
12	September 18, 2029	+14.0%	22.06	Upgraded light delivery software increases clinic procedural throughput, enabling ophthalmologists to treat more patients daily. The resulting efficiency gains drive faster consumable reorders and expand clinic-level returns on capital.
13	December 18, 2029	+10.0%	24.26	International commercial operations achieve meaningful scale, contributing double-digit percentage gains to total procedure volume. The geographic diversification of revenues cushions the business against localized reimbursement shifts and expands terminal market reach.
14	March 18, 2030	+12.0%	27.17	Full-year 2029 results showcase robust GAAP operating profits and double-digit return on invested capital. The market finally prices RxSight as an elite medical technology franchise rather than a struggling speculative enterprise.
15	June 18, 2030	+8.0%	29.35	Minimal ongoing maintenance capital expenditures allow expanding operating profits to convert directly into unencumbered free cash flow. Treasury reserves swell significantly, providing management with abundant capital allocation optionality for shareholder value creation.
16	September 18, 2030	+11.0%	32.58	Widening clinical adoption among cataract surgeons cements the Light Adjustable Lens as the undisputed premium standard. Institutional investors re-rate the equity toward peer-group multiples, acknowledging its unassailable technological and operational moat.
17	December 18, 2030	+7.0%	34.86	Strong year-end surgical volumes cap another highly profitable year, while clean balance sheet fundamentals insulate against macro volatility. Free cash flow margins expand toward 15%, demonstrating world-class owner economics and pricing durability.
18	March 18, 2031	+10.0%	38.34	Full-year 2030 financials highlight formidable compounding, with annual owner earnings surpassing $40 million. The company's pristine debt-free status and cash reserves draw enthusiastic comparisons to classic medical compounders with unshakeable moats.
19	June 18, 2031	+6.0%	40.64	Management actively evaluates initiating share repurchases as accumulated treasury cash comfortably outpaces internal reinvestment needs. Returning surplus cash to owners marks the ultimate vindication of the company's disciplined capital stewardship.
20	September 18, 2031	+9.0%	44.30	Terminal valuation multiples settle around fair value, reflecting a deeply entrenched, highly profitable franchise in premium ophthalmic surgery. The investment delivers massive long-term capital appreciation for patient, value-seeking equity owners.

Advisor and configuration

Advisor: warren_buffett__the_value_seeker__google_gemini_3_8_flash__20260902_ga_release
Persona: Warren Buffett
Archetype: The Value Seeker
Model: 2026-09-02 release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: warren_buffett__the_value_seeker__google_gemini_3_8_flash__20260902_ga_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: warren_buffett__the_value_seeker__google_gemini_3_8_flash__20260902_ga_release THINKER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Warren Buffett advisor methodology

Configuration components

aiassmprmtcmpnt_fd56cd0b-bb57-5546-a9af-5ff8cab13044
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Universal Investor — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.